Sputnik V Vaccine Developing Decision to Be Made in 2 Weeks

Alexander Gintsburg, the director of the Gamaleya Research Institute of Epidemiology and Microbiology, announced that the decision of developing the Sputnik V COVID-19 vaccine for resisting the recently emerged Omicron variant will be made in two weeks, RT reported on Thursday.

Gintsburg added that the center is working on isolating the virus, after that officials can make such a decision based on the results of scientific researches and studies.

Next, he asserted that Sputnik V vaccine is the most COVID-19 vaccine which is capable of producing antibodies against the virus.

It is worthy to mention, the Director of the Foreign Affairs’ Economic Cooperation Department Dmitry Birichevsky said on Tuesday that the state is expecting World Health Organization (WHO) approval for the Sputnik V COVID-19 vaccine in the first half of 2022.

Birichevsky explained, “We have been actively helping the Russian Direct Investment Fund to promote our vaccine Sputnik V in international markets. This is constant routine work, which requires attention and cooperation with embassies.

He added, “We still hope that the vaccine will be requalified by the WHO at some stage. I think it will be in the first half of next year.”

After that, the Russian official reflected that only one step is for WHO’s approval, which is the technical paperwork; “It means that business circles can go abroad more calmly knowing that our vaccine is approved not only by 71 countries. I hope that it will be recognized globally, and then the barriers that unfortunately exist at present will be eliminated,” Birichevsky explained.

The Sputnik V vaccine is approved and used in more than 71 countries around the world, and it is under the evaluation of the WHO and the European Medicines Agency (EMA).